ClinicalTrials.gg
RecruitingNCT06037980PURITYUpdated Sep 9, 2026

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

A Phase 2/3 interventional study of Gemcitabine and Nab paclitaxel in Biliary Tract Cancer and Cholangiocarcinoma, sponsored by Gruppo Oncologico del Nord-Ovest. Recruiting at 19 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Gruppo Oncologico del Nord-Ovest · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing gemcitabine in Biliary Tract Neoplasms — 9 open to participants now, 13 under way, 2 of them phase 3. Gemcitabine · Biliary Tract Neoplasms.

Planned enrollment
2nd of 49
300 · median 44
Started
2023
with 2 others
Phase 2/3
Only one
of the 49
Primary completion
2028-12
later than 12 of 12 live
Registered
41st of 49
by date

Among the 49 studies testing gemcitabine in Biliary Tract Neoplasms, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2023, is the only one in phase 2/3, reaches primary completion later than 12 of the 12 other live ones, and was the 41st registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

9 of the 49 studies testing gemcitabine in Biliary Tract Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gemcitabine in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in terms of 12-month PFS rate (phase II part) and PFS (phase III part) in patients with resectable BTC at high risk for recurrence.

Read the detailed description

PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in terms of 12-month PFS rate (phase II part) and PFS (phase III part) in patients with resectable BTC at high risk for recurrence.

High risk for recurrence, for which patients will be eligible for study, is defined by the presence of at least one of the following risk features, as evaluated at baseline (pre-surgery):

  1. For cholangiocarcinoma:

    • Suspected or definite locoregional lymph node involvement in the absence of jaundice (at least one of the following):

      • positive FNA cytology (obtained by EUS).
      • positive locoregional lymph nodes at PET-CT.
      • suspected positive locoregional lymph nodes at imaging (CT or MRI scan) according to local MTD discussion (eg. short axis > 1.5 cm, contrast enhancement uptake, round shape, restriction at DWI).
    • Macrovascular invasion at preoperative CT scan.
    • Expected R1 resection due to proximity to major intrahepatic vascular and biliary structures.
    • For iCCA, presence of satellitosis or multifocal disease or radiological suspicion of tumoral diaphragmatic adhesion.
    • For iCCA, size of the liver lesion >5 cm.
    • For eCCA, size of the primary lesion > 3cm.
    • Ca19.9 >100 U/mL.
  2. For GBC:

    • Incidentally Detected Gallbladder Carcinoma (IGBC) After Simple Cholecystectomy with indication for radical second surgery (>pT2) or newly diagnosed GBC.
03

Conditions studied

  • Biliary Tract Cancer
  • Cholangiocarcinoma

Keywords

  • Biliary Tract Cancers
  • Cholangiocarcinoma
  • Neoadjuvant Chemotherapy
  • Cisplatin Gemcitabine Nabpaclitaxel
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient able and willing to provide written and to comply with the study protocol and with the planned surgical procedures.
  2. Female and male patients ≥18 years and \<75 years.
  3. or cytologically confirmed non resectable carcinoma of biliary tract (BTC), including gallbladder carcinoma (GBC), intrahepatic, periperihilar or distal Cholangiocarcinoma (CCA). Mixed tumor entities with hepatocellular carcinoma and ampullary cancers are excluded.
  4. Availability of a tumoral sample
  5. performance status of 0-1.
  6. No prior tumor resection for BTC.
  7. Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax and PET scan.
  8. Technically resectable BTC as per local Multidisciplinary Team (MDT) assessment, including a core team with at least one medical oncologist, one surgeon, one radiologist, one endoscopist/gastroenterologist and one pathologist, all with expertise > 3 years on biliary tract cancer and hepatobiliary oncology.
  9. High risk for recurrence defined as the presence of at least one of the following risk features, as evaluated at baseline (pre-surgery):

    1. For cholangiocarcinoma:

      • Suspected or definite locoregional lymph node involvement (at least one of the following):

        • positive FNA cytology (obtained by EUS).
        • positive locoregional lymph nodes at PET-CT.
        • suspected positive locoregional lymph nodes at imaging (CT or MRI scan) according to local MDT discussion (eg. short axis > 1.5 cm, contrast enhancement uptake, round shape, restriction at DWI).
      • Macrovascular invasion at preoperative CT scan.
      • Expected R1 resection due to proximity to major intrahepatic vascular and biliary structures.
      • For iCCA, presence of satellitosis or multifocal disease or radiological suspicion of tumoral diaphragmatic adhesion.
      • For iCCA, size of the liver lesion >5 cm.
      • For eCCA, size of the primary lesion > 3cm.
      • Ca19.9 >100 U/mL.
    2. For GBC:

      • Incidentally Detected Gallbladder Carcinoma (IGBC) after simple cholecystectomy with indication for radical second surgery (>pT2) or newly diagnosed GBC.
  10. Estimated > 3 months.
  11. Adequate baseline hematologic function characterized by the following at screening:

    1. ≥ 1.5 × 109/L
    2. ≥ 100 × 109/L
    3. ≥ 9 g/dl. Note: prior transfusions for patients with low hemoglobin are allowed.
  12. Adequate liver function characterized by the following at screening:

    1. Serum total ≤ 1.5 × and \< 2 mg/dL. Note: Subjects with Serum total bilirubin ≥ 1.5 × ULN and conjugated bilirubin ≤ ULN or \< 40% of total bilirubin are allowed.
    2. Serum transaminases ( and/or ALT) \< 3 x ULN.
  13. Adequate renal function, i.e. serum creatinine ≤ 1.5 x institutional ULN and calculated by Cockroft-Gault formula or directly measured ≥ 50 mL/min
  14. Adequate coagulation functions as defined by (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).
  15. No presence of complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency with DPYD gene testing mandatory at screening as per national guidelines
  16. Females of must agree to remain abstinent (refrain from sexual intercourse) or use highly effective methods, as defined in APPENDIX V of the full protocol, during the treatment period and for at least 7 months after the last administration of study treatments.
  17. Males must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods, as defined in APPENDIX V of the full protocol.
  18. Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women \<1 year after the onset of menopause.
  19. A participant must agree not to donate eggs/sperm for future use for the purposes of assisted reproduction during the study and for a period of 7 months after receiving the last dose of study treatment. Female and male participants should consider preservation of eggs/sperm prior to study treatment as anti-cancer treatments may impair fertility.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to any of the study drugs.
  2. Any known additional that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry except for curatively treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, and prostate cancer.
  3. Locally unresectable tumor according to local MDT (including radiological evidence suggesting inability to resect with curative intent whilst maintaining adequate vascular inflow and outflow, and sufficient future liver remnant).
  4. Evidence of distant at any site.
  5. Tumors requiring multi-step surgical procedures such as two-stage hepatectomy or Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS) due to liver volumetry-based assessment of anticipated inadequate future liver remnant.
  6. Cirrhosis at a level of B (or worse) or cirrhosis (any degree) and a history of hepatic decompensation in the year before enrolment.
  7. Know active uncontrolled or . Patients with a past or resolved HBV infection are eligible. Patients with chronic disease controlled by antiviral therapy or requiring prophylactic treatment are eligible.
  8. Chronic or current active infectious disease requiring systemic antibiotics or antifungal treatment within 2 weeks prior to enrollment.
  9. Known uncontrolled infection. HIV-positive patients are eligible if their amounts to 300 cells per μL or more; HIV viral load must be undetectable per standard of care assay, and they must be compliant with antiretroviral treatment.
  10. Pregnant or breast-feeding patient, or patient is planning to become pregnant within 7 months after the end of treatment.
  11. Any other concurrent antineoplastic treatment including radiotherapy.
  12. Previous or concurrent systemic (eg cytotoxic or targeted or other experimental drugs) therapy for BTC.
  13. Prior surgery or locoregional therapy for BTC.
  14. Severe or uncontrolled cardiovascular disease (congestive heart failure III or IV, unstable angina pectoris, history of myocardial infarction in the last three months, significant arrhythmia).
  15. Presence of psychiatric disorder precluding understanding of information of trial related topics and giving .
  16. Any serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial.
  17. Presence of complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency with DPYD gene testing mandatory at screening as per national guidelines.
  18. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Preoperative chemotherapy

    Triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment followed by surgery and adjuvant chemotherapy

    Drug: Gemcitabine · Drug: Nab paclitaxel · Drug: Cisplatin · Procedure: Curative Surgery · Drug: Capecitabine

  • Active comparator
    Upfront surgery

    Standard upfront surgery and adjuvant chemotherapy

    Procedure: Curative Surgery · Drug: Capecitabine

Interventions

  • ◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles

    Also known as: Abraxane

  • ◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles

  • ProcedureCurative Surgery

    Curative surgery on primary tumor

  • 1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles

06

What researchers measure

Primary outcomes

  1. 12-month progression-free survival (PFS) rate

    the proportion of patients alive and free from progression/post-resection recurrence by 12-months timepoint from randomization (to be considered as primary endpoint in the phase II part of the study and as secondary endpoint in the phase III part of the study).

    Time frame: 12 months

  2. median PFS

    i.e. the time from randomization to disease progression, post-resection recurrence or death from any cause (to be considered as secondary endpoint in the phase II part of the study and as primary endpoint in the phase III part of the study).

    Time frame: From date of randomization until the date of first documented progression (as assessed by radiological evaluation and clinical examination) or date of death from any cause, whichever came first, assessed up to 120 months

Secondary outcomes

  1. Median event free survival

    i.e. the time from randomization to disease progression that precludes definitive surgery, treatment discontinuation for any reason, post-resection recurrence, a second primary cancer, or death from any cause.

    Time frame: from date of randomization to disease progression that precludes definitive surgery, treatment discontinuation for any reason, post-resection recurrence, diagnosis of second cancer, or death from any cause, assessed up to 120 months

  2. Median relapse free survival

    i.e. the time from surgery to disease recurrence or death in patients who undergo to surgery with curative intent.

    Time frame: from date of surgery to date of disease recurrence or date of death, whichever came first, in patients who undergo surgery with curative intent, assessed up to 120 months.

  3. Median Overall survival

    i.e. the time from randomization to death or last follow-up for alive patients.

    Time frame: from date of randomization to date of death (or last follow up for alive patients), assessed up to 120 months.

  4. R0 resection rate

    i.e. the percentage of patients, relative to the total of randomized patients, for whom a R0 resection is achieved.

    Time frame: At surgery

  5. R0+R1 resection rate

    i.e. the percentage of patients, relative to the total of randomized patients, for whom the tumor was macroscopically removed and the intent of surgery is considered curative.

    Time frame: At surgery

  6. Quality of life EORTC QLQ-C30 scores

    QoL will be estimated with EORTC QLQ-C30; mean score changes from baseline, proportion of patients with improved, stable, or deteriorated scores from baseline and time to deterioration in the EORTC QLQ-C30 scores will be compared between the two arms. Time to deterioration will be defined as the time from baseline to the first onset of a 10-point or greater decrease (for functional scales)/increase (for symptoms scale) from baseline, with confirmation under the right-censoring rule. All available observations will be used to calculate time to deterioration.

    Time frame: Quality of life questionnaires will be compiled during screening (28 days before randomisation) and at restaging before (week 8 to 10 after randomisation) and after surgery (week 6 to 16 after surgery)

  7. Quality of life BIL21 scores

    QoL will be estimated with the module BIL21; mean score changes from baseline, proportion of patients with improved, stable, or deteriorated scores from baseline and time to deterioration in the BIL21 physical functioning, social functioning, and fatigue scores will be compared between the two arms. Time to deterioration was defined as the time from baseline to the first onset of a 10-point or greater decrease from baseline for functional scales or a 10-point or greater increase for symptom scales, with confirmation under the right-censoring rule. All available observations will be used to calculate time to deterioration.

    Time frame: Quality of life questionnaires will be compiled during screening (28 days before randomisation) and at restaging before (week 8 to 10 after randomisation) and after surgery (week 6 to 16 after surgery)

  8. Overall response rate

    of neoadjuvant therapy as per investigator assessment and central review, i.e. the percentage of patients, relative to the total of enrolled subjects receiving neoadjuvant treatment, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria.

    Time frame: At radiological evaluation as performed at restaging before surgery (week 8 to 10 after randomisation)

  9. Resectability rate of primary tumor

    i.e. the retrospective evaluation of patients with unresectable disease, as assessed by the central review committee, in the two arms, and of the rate of conversion to resectability in the neoadjuvant arm.

    Time frame: Resectability rate will be assessed before surgery (after the 3 cycles of neoadjuvant chemotherapy for the experimental treatment arm)

  10. Toxicity rates

    .e. the percentage of patients, relative to the total of subjects randomized to neoadjuvant treatment, experiencing a specific adverse event, according to National Cancer Institute Common Toxicity Criteria (version 5.0).

    Time frame: Through study completion, an average of 1 year for each patient

  11. Perioperative morbidity and mortality

    i.e. the percentage of patients, relative to the total of enrolled subjects undergoing surgery, with any serious perioperative morbidity or mortality according to Clavien-Dindo classification.

    Time frame: At surgery

07

Study locations

2 of 19 sites recruiting
  • Ospedali Riuniti di Ancona
    Ancona, Italy
    Not yet recruiting
    • Rossana Berardi · Contact
  • ASST Papa Giovanni XXIII
    Bergamo, Italy
    Not yet recruiting
    • Stefania Mosconi · Contact
  • Oncologia Medica Policlinico Sant'Orsola - Malpighi
    Bologna, Italy
    Not yet recruiting
    • Giovanni Brandi · Contact
  • ASST Spedali Civili
    Brescia, Italy
    Not yet recruiting
    • Giuseppina Arcangeli · Contact
  • Azienda Ospedaliera S. Croce e Carle
    Cuneo, Italy
    Not yet recruiting
    • Elena Fea · Contact
  • IRST Dino Amadori
    Meldola, Italy
    Not yet recruiting
    • Ilario Giovanni Rapposelli · Contact
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
    Recruiting
  • Humanitas Cancer Center
    Milan, Italy
    Not yet recruiting
    • Lorenza Rimassa · Contact
  • Ospedale Niguarda Cancer Center
    Milan, Italy
    Not yet recruiting
    • Salvatore Siena · Contact
  • Ospedale San Raffaele
    Milan, Italy
    Not yet recruiting
    • Andrea Casadei Gardini · Contact
  • Università di Modena
    Modena, Italy
    Not yet recruiting
    • Massimilano Salati · Contact
  • Ospedale S. Gerardo
    Monza, Italy
    Not yet recruiting
    • Raffaella Longarini · Contact
  • IOV
    Padova, Italy
    Not yet recruiting
    • Francesca Bergamo · Contact
  • Policlinico San Matteo
    Pavia, Italy
    Not yet recruiting
    • Salvatore Corallo · Contact
  • Azienda Ospedaliera Universitaria Pisa
    Pisa, Italy
    Recruiting
    • Lorenzo Fornaro · Contact
  • IRST (Cesena-Forlì-Meldola)
    Ravenna, Italy
    Not yet recruiting
    • Stefano Tamberi · Contact
  • Policlinico Gemelli
    Rome, Italy
    Not yet recruiting
    • Lisa Salvatore · Contact
  • Azienda Ospedaliera Ordine Mauriziano
    Turin, Italy
    Not yet recruiting
    • Massimo Di Maio · Contact
  • AOUI Verona - Policlinico "G.B. Rossi"
    Verona, Italy
    Not yet recruiting
    • Davide Melisi · Contact
08

References and documents

Publications

  • Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019 Aug;45(8):1432-1438. doi: 10.1016/j.ejso.2019.03.023. Epub 2019 Mar 21. PubMed 30914290 ↗
  • Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270. PubMed 30998813 ↗
  • Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct;30(11):6558-6566. doi: 10.1245/s10434-023-13809-5. Epub 2023 Jun 27. PubMed 37368098 ↗
  • Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6. PubMed 38589856 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2028, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Sep 14, 2023
StartActual
Nov 7, 2023
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06037980
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Responsible party
Sponsor
First posted
Sep 14, 2023
Start date
Nov 7, 2023
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 9, 2026

Study contacts

Monica Niger, MD
Contact
monica.niger@istitutotumori.mi.it
02 2390 2919
Monica Niger, MD
principal investigator · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Monica Niger, MD
principal investigator · 02 2390 2919

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion